Lana Marie Chahine, MD
Neurology · Pittsburgh
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 21 years
- Graduated 2005
Offices
1 location · University of Pittsburgh Physicians · 4,166 clinicians in this group
Looking this up.
Hospitals listed: Upmc Presbyterian Shadyside. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chahine’s office at (412) 692-4920 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Upmc Presbyterian ShadysidePittsburgh, PAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of UPMC, which runs 34 hospitals in 3 statesHome of UPMC Hillman Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.4 (1.22 to 1.57), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.84 (1.45 to 2.22) · 11,546 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.481, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.755, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.597, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.355, Oct 2024 – Sep 2025
See every measure and the patient survey for Upmc Presbyterian Shadyside
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 1 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.4 (1.22 to 1.57) | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.84 (1.45 to 2.22) · 11,546 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.481 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.755 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.597 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.355 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0.25 to 1.55) · 4,065 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.94 (137.62 to 198.26) · 391 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 156 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.6 · 423 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 718 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 8,785 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,123 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.23 to 0.56) · 14,320 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (1.9 to 4.41) · 4,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.71 (0.65 to 2.78) · 2,630 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (1.31 to 3.29) · 4,417 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.58 (7.41 to 13.74) · 2,469 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.69 (3.73 to 7.65) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.67 to 3.01) · 1,552 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 387 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.86 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 664 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.1 · 1,405 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2.8 · 212 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -16.5 · 523 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.7 · 425 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.7 · 1,228 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3.1 to 6.8) · 213 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.1 (5.9 to 10.8) · 213 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.6 · 383 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.7 · 262 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 439 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.2 (8.8 to 14.2) · 2,561 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 1,016 cases | No different | Jan 2024 – Dec 2024 |
What patients said (612 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$17,011
Medicare paid this office $17,011 for 69 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 39 | $3,741 | $81 |
| Long return visit (40+ min) | 21 | $2,625 | $109 |
Who their Medicare patients are
69 Original Medicare patients in 2024. Average age 73 · Women 44% · Health risk score 1.58. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 64% · Depression 41% · Coronary heart disease 30% · Atrial fibrillation 17% · Cancer 16%.
The office billed $54,997, Medicare allowed $23,482 and paid $17,011; for 1,610 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 69 | 1,610 | 73 | 1.58 | $54,997 | $17,011 |
| 2023 | 66 | 397 | 73 | 1.72 | $30,479 | $10,960 |
| 2022 | 59 | 400 | 71 | 1.46 | $31,089 | $11,645 |
| 2021 | 57 | 587 | 71 | 1.86 | $28,062 | $11,096 |
| 2020 | 58 | 77 | 70 | 1.73 | $16,213 | $4,915 |
| 2019 | 77 | 1,220 | 70 | 1.71 | $52,866 | $16,293 |
| 2018 | 71 | 930 | 68 | 1.60 | $44,672 | $15,060 |
| 2017 | 164 | 6,182 | 72 | 1.68 | $152,603 | $52,666 |
| 2016 | 173 | 5,520 | 72 | 1.67 | $159,076 | $54,127 |
| 2015 | 206 | 7,670 | 71 | 1.59 | $198,631 | $65,241 |
| 2014 | 219 | 4,575 | 73 | 1.64 | $141,437 | $53,345 |
| 2013 | 122 | 774 | 75 | 1.85 | $38,358 | $15,776 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 39 | $3,955 | $78 |
| Long return visit (40+ min) | 22 | $3,472 | $124 |
2022: 2 services
| Long return visit (40+ min) | 18 | $3,688 | $137 |
| Return visit (30+ min) | 27 | $3,321 | $90 |
2021: 3 services
| Return visit (30+ min) | 31 | $3,656 | $99 |
| Long return visit (40+ min) | 11 | $2,011 | $144 |
| Short return visit (20+ min) | 12 | $834 | $60 |
2020: 2 services
| Return visit (30+ min) | 15 | $1,212 | $67 |
| Short return visit (20+ min) | 13 | $566 | $40 |
2019: 4 services
| Return visit (30+ min) | 25 | $2,437 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,059 | $147 |
| New patient visit (45+ min) | 11 | $1,201 | $109 |
| Long return visit (40+ min) | 12 | $1,136 | $95 |
2018: 3 services
| New patient visit (45+ min) | 14 | $1,777 | $127 |
| Return visit (30+ min) | 16 | $1,538 | $77 |
| New patient visit (30+ min) | 13 | $919 | $71 |
2017: 5 services
| Botox | 11 | $27,085 | None |
| Return visit (30+ min) | 91 | $10,715 | $81 |
| New patient visit (60+ min) | 14 | $2,271 | $162 |
| Short return visit (20+ min) | 25 | $1,723 | $57 |
| Long return visit (40+ min) | 14 | $1,675 | $112 |
2016: 5 services
| Botox | 11 | $21,858 | None |
| Return visit (30+ min) | 91 | $10,882 | $78 |
| Long return visit (40+ min) | 24 | $3,403 | $113 |
| New patient visit (60+ min) | 20 | $3,291 | $165 |
| Short return visit (20+ min) | 19 | $1,402 | $54 |
2015: 9 services
| Botox | 16 | $27,027 | None |
| Return visit (30+ min) | 80 | $8,893 | $82 |
| New patient visit (60+ min) | 19 | $3,239 | $170 |
| Short return visit (20+ min) | 38 | $2,256 | $52 |
| Long return visit (40+ min) | 16 | $2,174 | $114 |
| New patient visit (45+ min) | 13 | $1,683 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,303 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,022 | $60 |
| Return visit (30+ min) | 15 | $913 | $61 |
2014: 10 services
| Botox | 13 | $17,564 | None |
| Return visit (30+ min) | 65 | $7,594 | $83 |
| New patient visit (60+ min) | 23 | $3,458 | $150 |
| New patient visit (45+ min) | 26 | $3,403 | $131 |
| Long return visit (40+ min) | 23 | $2,869 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,617 | $164 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,355 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,489 | $60 |
| Short return visit (20+ min) | 23 | $1,457 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,201 | $86 |
2013: 7 services
| Long return visit (40+ min) | 14 | $1,658 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,504 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,344 | $112 |
| Return visit (30+ min) | 12 | $1,235 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,088 | $84 |
| Short return visit (20+ min) | 14 | $845 | $60 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $385 | $32 |
Drugs they prescribed that Part D paid
$122,461
Pharmacies billed $122,461 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 495) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
479 generic and 16 brand-name prescriptions · $122,461 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ingrezza | 12 | $100,625 | $8,385 |
| Carbidopa-Levodopa | 179 | $6,980 | $39 |
| Droxidopa | 13 | $4,118 | $317 |
| Selegiline | 22 | $2,803 | $127 |
| Carbamazepine | 13 | $1,032 | $79 |
See all 14 drugs
| Ingrezza | 12 | $100,625 | $8,385 |
| Carbidopa-Levodopa | 179 | $6,980 | $39 |
| Droxidopa | 13 | $4,118 | $317 |
| Selegiline | 22 | $2,803 | $127 |
| Carbamazepine | 13 | $1,032 | $79 |
| Gabapentin | 51 | $563 | $11 |
| Entacapone | 13 | $531 | $41 |
| Clonazepam | 27 | $380 | $14 |
| Propranolol | 26 | $296 | $11 |
| Carbidopa-Levodopa Er | 16 | $273 | $17 |
| Primidone | 16 | $223 | $14 |
| Venlafaxine Hcl Er | 12 | $205 | $17 |
| Donepezil | 29 | $151 | $5 |
| Duloxetine | 11 | $145 | $13 |
Year by year
| 2024 | 495 | 85 | 0% (0) | 3% | $122,461 |
| 2023 | 420 | 71 | 0% (0) | 4% | $103,679 |
| 2022 | 551 | 85 | 0% (0) | 6% | $178,855 |
| 2021 | 511 | 82 | None | 7% | $184,495 |
| 2020 | 600 | 93 | None | 8% | $431,162 |
| 2019 | 366 | 70 | 0% (0) | 11% | $238,421 |
| 2018 | 463 | 107 | 0% (0) | 11% | $108,091 |
| 2017 | 1,339 | 147 | None | 14% | $239,835 |
| 2016 | 1,349 | 163 | None | None | $240,738 |
| 2015 | 1,113 | 151 | None | None | $300,802 |
| 2014 | 760 | 119 | None | 20% | $244,745 |
| 2013 | 430 | 68 | None | 24% | $344,117 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Droxidopa | None | 14 | $27,328 | $1,952 |
| Rytary | Parkinson's | 11 | $15,926 | $1,448 |
| Carbidopa-Levodopa | None | 174 | $7,586 | $44 |
| Selegiline | None | 26 | $4,521 | $174 |
| Carbamazepine | None | 12 | $1,430 | $119 |
| Amantadine | None | 18 | $748 | $42 |
| Gabapentin | None | 40 | $535 | $13 |
| Propranolol | None | 16 | $399 | $25 |
| Venlafaxine Hcl Er | None | 16 | $256 | $16 |
| Primidone | None | 13 | $215 | $17 |
| Donepezil | None | 14 | $91 | $7 |
| Clonazepam | None | 14 | $60 | $4 |
2022: 13 drugs
| Ingrezza | 14 | $97,837 | $6,988 |
| Droxidopa | 12 | $26,215 | $2,185 |
| Carbidopa-Levodopa | 228 | $11,400 | $50 |
| Selegiline | 32 | $3,903 | $122 |
| Carbamazepine | 16 | $1,636 | $102 |
| Propranolol | 36 | $1,471 | $41 |
| Carbidopa-Levodopa Er | 20 | $1,316 | $66 |
| Amantadine | 21 | $1,224 | $58 |
| Primidone | 17 | $708 | $42 |
| Gabapentin | 46 | $554 | $12 |
| Donepezil | 28 | $302 | $11 |
| Venlafaxine Hcl Er | 14 | $218 | $16 |
| Clonazepam | 16 | $100 | $6 |
2021: 15 drugs
| Ingrezza | 14 | $102,084 | $7,292 |
| Droxidopa | 11 | $41,080 | $3,735 |
| Carbidopa-Levodopa | 183 | $10,838 | $59 |
| Carbidopa-Levodopa-Entacapone | 17 | $5,149 | $303 |
| Selegiline | 15 | $2,314 | $154 |
| Carbamazepine | 13 | $1,673 | $129 |
| Amantadine | 22 | $1,237 | $56 |
| Carbidopa-Levodopa Er | 17 | $1,085 | $64 |
| Propranolol | 16 | $1,071 | $67 |
| Gabapentin | 38 | $760 | $20 |
| Donepezil | 36 | $407 | $11 |
| Venlafaxine Hcl Er | 19 | $366 | $19 |
| Primidone | 17 | $331 | $19 |
| Propranolol Hcl Er | 14 | $283 | $20 |
| Quetiapine | 12 | $94 | $8 |
2020: 15 drugs
| Ingrezza | 25 | $167,703 | $6,708 |
| Carbidopa-Levodopa | 215 | $10,267 | $48 |
| Carbidopa-Levodopa Er | 39 | $2,186 | $56 |
| Amantadine | 33 | $1,811 | $55 |
| Carbamazepine | 12 | $1,373 | $114 |
| Propranolol Hcl Er | 35 | $943 | $27 |
| Pramipexole Dihydrochloride | 19 | $634 | $33 |
| Topiramate | 14 | $398 | $28 |
| Propranolol | 11 | $359 | $33 |
| Primidone | 17 | $297 | $17 |
| Gabapentin | 19 | $283 | $15 |
| Donepezil | 14 | $266 | $19 |
| Venlafaxine Hcl Er | 11 | $262 | $24 |
| Quetiapine | 20 | $114 | $6 |
| Clonazepam | 18 | $84 | $5 |
2019: 9 drugs
| Ingrezza | 15 | $99,207 | $6,614 |
| Carbidopa-Levodopa | 141 | $6,335 | $45 |
| Carbidopa-Levodopa-Entacapone | 11 | $3,443 | $313 |
| Entacapone | 12 | $3,258 | $272 |
| Carbidopa-Levodopa Er | 26 | $1,096 | $42 |
| Levetiracetam | 16 | $1,079 | $67 |
| Propranolol Hcl Er | 20 | $750 | $38 |
| Topiramate | 11 | $313 | $28 |
| Trazodone | 11 | $101 | $9 |
2018: 9 drugs
| Carbidopa-Levodopa | 149 | $10,207 | $69 |
| Amantadine | 18 | $2,390 | $133 |
| Carbidopa-Levodopa-Entacapone | 16 | $980 | $61 |
| Propranolol Hcl Er | 11 | $759 | $69 |
| Carbidopa-Levodopa Er | 15 | $748 | $50 |
| Donepezil | 48 | $673 | $14 |
| Gabapentin | 18 | $588 | $33 |
| Levetiracetam | 12 | $409 | $34 |
| Venlafaxine Hcl Er | 16 | $215 | $13 |
2017: 24 drugs
| Nuplazid | Parkinson's psychosis | 16 | $35,005 | $2,188 |
| Rasagiline Mesylate | None | 34 | $31,332 | $922 |
| Rytary | Parkinson's | 12 | $26,484 | $2,207 |
| Carbidopa-Levodopa | None | 394 | $19,742 | $50 |
| Azilect | None | 20 | $19,316 | $966 |
| Carbidopa-Levodopa-Entacapone | None | 36 | $14,771 | $410 |
| Carbidopa | None | 16 | $13,236 | $827 |
| Amantadine | None | 80 | $11,810 | $148 |
| Entacapone | None | 44 | $9,862 | $224 |
| Pramipexole Er | None | 15 | $9,813 | $654 |
| Ropinirole Er | None | 25 | $4,696 | $188 |
| Selegiline | None | 25 | $4,030 | $161 |
| Carbidopa-Levodopa Er | None | 39 | $2,144 | $55 |
| Donepezil | None | 132 | $1,678 | $13 |
| Gabapentin | None | 49 | $1,436 | $29 |
| Mirtazapine | None | 43 | $981 | $23 |
| Pyridostigmine | None | 21 | $870 | $41 |
| Venlafaxine Hcl Er | None | 64 | $711 | $11 |
| Propranolol | None | 15 | $509 | $34 |
| Fludrocortisone Acetate | None | 19 | $456 | $24 |
| Quetiapine | None | 25 | $300 | $12 |
| Sertraline | None | 29 | $263 | $9 |
| Butalbital-Acetaminophen-Caffe | None | 12 | $180 | $15 |
| Clonazepam | None | 20 | $151 | $8 |
2016: 21 drugs
| Azilect | 67 | $71,215 | $1,063 |
| Carbidopa | 27 | $26,667 | $988 |
| Carbidopa-Levodopa | 406 | $15,417 | $38 |
| Carbidopa-Levodopa-Entacapone | 31 | $10,639 | $343 |
| Entacapone | 51 | $9,220 | $181 |
| Amantadine | 64 | $7,899 | $123 |
| Ropinirole Er | 13 | $2,464 | $190 |
| Carbidopa-Levodopa Er | 74 | $2,254 | $30 |
| Donepezil | 83 | $1,506 | $18 |
| Selegiline | 18 | $1,448 | $80 |
| Gabapentin | 86 | $1,422 | $17 |
| Venlafaxine Hcl Er | 54 | $1,223 | $23 |
| Pyridostigmine | 14 | $1,116 | $80 |
| Mirtazapine | 43 | $876 | $20 |
| Propranolol | 20 | $724 | $36 |
| Clonazepam | 53 | $718 | $14 |
| Midodrine | 12 | $612 | $51 |
| Fludrocortisone Acetate | 13 | $403 | $31 |
| Quetiapine | 29 | $327 | $11 |
| Bupropion Xl | 17 | $180 | $11 |
| Sertraline | 19 | $169 | $9 |
2015: 20 drugs
| Azilect | 69 | $58,164 | $843 |
| Carbidopa | 20 | $24,330 | $1,217 |
| Carbidopa-Levodopa | 336 | $17,260 | $51 |
| Amantadine | 54 | $11,453 | $212 |
| Carbidopa-Levodopa-Entacapone | 32 | $9,642 | $301 |
| Ropinirole Er | 28 | $5,601 | $200 |
| Carbidopa-Levodopa Er | 81 | $2,581 | $32 |
| Pramipexole Dihydrochloride | 13 | $1,311 | $101 |
| Gabapentin | 41 | $763 | $19 |
| Donepezil | 56 | $703 | $13 |
| Venlafaxine Hcl Er | 29 | $607 | $21 |
| Quetiapine | 36 | $535 | $15 |
| Topiramate | 12 | $487 | $41 |
| Fludrocortisone Acetate | 11 | $430 | $39 |
| Clonazepam | 42 | $384 | $9 |
| Propranolol | 18 | $346 | $19 |
| Mirtazapine | 17 | $311 | $18 |
| Sertraline | 22 | $177 | $8 |
| Primidone | 13 | $95 | $7 |
| Trazodone | 13 | $63 | $5 |
2014: 15 drugs
| Azilect | 60 | $46,212 | $770 |
| Carbidopa-Levodopa | 261 | $14,731 | $56 |
| Carbidopa-Levodopa-Entacapone | 37 | $14,571 | $394 |
| Amantadine | 45 | $9,195 | $204 |
| Exelon | 12 | $5,633 | $469 |
| Ropinirole | 26 | $4,870 | $187 |
| Carbidopa-Levodopa Er | 38 | $1,515 | $40 |
| Pramipexole Dihydrochloride | 21 | $899 | $43 |
| Quetiapine | 20 | $627 | $31 |
| Venlafaxine Hcl Er | 18 | $620 | $34 |
| Donepezil | 32 | $454 | $14 |
| Gabapentin | 24 | $449 | $19 |
| Clonazepam | 20 | $194 | $10 |
| Trazodone | 12 | $99 | $8 |
| Propranolol | 12 | $71 | $6 |
2013: 8 drugs
| Azilect | 30 | $24,348 | $812 |
| Carbidopa-Levodopa-Entacapone | 36 | $15,134 | $420 |
| Carbidopa-Levodopa | 142 | $10,391 | $73 |
| Ropinirole | 37 | $5,133 | $139 |
| Amantadine | 18 | $2,914 | $162 |
| Quetiapine | 20 | $1,052 | $53 |
| Pramipexole Dihydrochloride | 14 | $987 | $71 |
| Escitalopram | 12 | $339 | $28 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biogen, Inc. · Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2020 | Their institution | $258,500 |
| Biogen, Inc. · Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2019 | Their institution | $203,583 |
| Biogen, Inc. · Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2021 | Their institution | $168,966 |
| Biogen, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With An Active-Treatment Dose-Blinded Period, To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Subjects With Parkinson'S Disease · 2022 | Their institution | $2,252 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 77.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1962672238
- Licence
- PA MD439624
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 3471 5th Ave Bldg Suite111, Suite 810 Lkb, Pittsburgh, PA, 15213
- NPI first listed
- 2008-03-03
- NPI last updated
- 2026-04-28
- NPI record certified
- 2026-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3471 5th Ave Bldg Suite111, Pittsburgh, PA, 15213
This office lists an electronic records connection.